QQQ   444.02 (-0.18%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.02 (-0.18%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.02 (-0.18%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.02 (-0.18%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

$2.50
+0.12 (+5.04%)
(As of 01:17 PM ET)
Today's Range
$2.38
$2.50
50-Day Range
$2.37
$2.80
52-Week Range
$1.81
$3.57
Volume
4,812 shs
Average Volume
9,603 shs
Market Capitalization
$202.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.83

Innate Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
313.2% Upside
$9.83 Price Target
Short Interest
Bearish
0.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Innate Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

624th out of 939 stocks

Biological Products, Except Diagnostic Industry

107th out of 156 stocks

IPHA stock logo

About Innate Pharma Stock (NASDAQ:IPHA)

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

IPHA Stock Price History

IPHA Stock News Headlines

Innate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC Wainwright
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
IPHYF Innate Pharma S.A.
Innate Pharma SA ADR
Innate Pharma CEO Mahjoubi to leave company
See More Headlines
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IPHA
Fax
N/A
Employees
191
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.83
High Stock Price Target
$11.50
Low Stock Price Target
$8.00
Potential Upside/Downside
+309.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$66.71 million
Book Value
$0.69 per share

Miscellaneous

Free Float
55,074,000
Market Cap
$194.06 million
Optionable
Not Optionable
Beta
0.28
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Herve Brailly Ph.D. (Age 63)
    Co-Founder, Interim CEO & Chairman of Executive Board
  • Mr. Yannis Morel Ph.D. (Age 51)
    Executive VP, COO & Member of Executive Board
    Comp: $404.88k
  • Dr. François Romagné Ph.D. (Age 60)
    Founder
  • Mr. Eric Vivier D.V.M. (Age 60)
    M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer
  • Dr. Marc Bonneville Ph.D. (Age 64)
    Founder
  • Mr. Jean Jacques Fournié Ph.D.
    Founder
  • Mr. Alessandro Moretta M.D.
    Ph.D., Founder
  • Mr. Frederic Lombard M.B.A. (Age 49)
    Senior VP & CFO
  • Dr. Sonia Quaratino M.D. (Age 62)
    Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board
  • Mr. Arvind Sood
    Executive VP, President of US Operations & Member of Executive Board

IPHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Innate Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IPHA shares.
View IPHA analyst ratings
or view top-rated stocks.

What is Innate Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for Innate Pharma's stock. Their IPHA share price targets range from $8.00 to $11.50. On average, they expect the company's stock price to reach $9.83 in the next twelve months. This suggests a possible upside of 313.2% from the stock's current price.
View analysts price targets for IPHA
or view top-rated stocks among Wall Street analysts.

How have IPHA shares performed in 2024?

Innate Pharma's stock was trading at $2.80 at the beginning of the year. Since then, IPHA shares have decreased by 15.0% and is now trading at $2.38.
View the best growth stocks for 2024 here
.

Are investors shorting Innate Pharma?

Innate Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 89,100 shares, an increase of 13.6% from the February 29th total of 78,400 shares. Based on an average trading volume of 11,700 shares, the short-interest ratio is currently 7.6 days.
View Innate Pharma's Short Interest
.

What is Hervé Brailly's approval rating as Innate Pharma's CEO?

4 employees have rated Innate Pharma Chief Executive Officer Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among the company's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and

When did Innate Pharma IPO?

Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO.

Who are Innate Pharma's major shareholders?

Innate Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Exchange Traded Concepts LLC (0.06%) and Optiver Holding B.V. (0.03%).

How do I buy shares of Innate Pharma?

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPHA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners